New Delhi, Oct. 29 -- New Delhi: India's healthcare industry and public health experts have warned that price cuts of non-scheduled cancer medicines effective 9 November under the National Pharmaceutical Pricing Authority's trade margin rationalization exercise are structurally flawed, legitimize profiteering and completely bypass high-cost patented drugs.

One-off, self-reported price revisions without independent verification will fail to deliver lasting relief, health groups said, demanding comprehensive, cost-based price controls covering all oncology therapies, permanent statutory margin caps across distribution channels and full scrutiny of company assistance programmes.

They also urged the government to mandate supply-chain data a...